Primary |
Product Used For Unknown Indication |
30.9% |
Staphylococcal Infection |
10.4% |
Cellulitis |
9.1% |
Osteomyelitis |
8.0% |
Pneumonia |
6.7% |
Infection |
5.7% |
Endocarditis |
3.7% |
Sepsis |
2.8% |
Staphylococcal Bacteraemia |
2.8% |
Drug Use For Unknown Indication |
2.5% |
Device Related Infection |
2.3% |
Pyrexia |
2.2% |
Pain |
2.0% |
Prophylaxis |
1.9% |
Febrile Neutropenia |
1.7% |
Antibiotic Prophylaxis |
1.5% |
Bacterial Infection |
1.5% |
Wound Infection |
1.5% |
Anaesthesia |
1.3% |
Evidence Based Treatment |
1.3% |
|
Renal Failure Acute |
15.6% |
Rash |
10.1% |
Drug Hypersensitivity |
6.8% |
Urticaria |
5.9% |
Red Man Syndrome |
5.7% |
Thrombocytopenia |
5.5% |
Blood Creatinine Increased |
4.9% |
Linear Iga Disease |
4.5% |
Pruritus |
4.5% |
Renal Tubular Necrosis |
4.4% |
Nephropathy Toxic |
4.3% |
Pyrexia |
3.8% |
Neutropenia |
3.5% |
Toxic Epidermal Necrolysis |
3.5% |
White Blood Cell Count Decreased |
3.3% |
Tubulointerstitial Nephritis |
3.1% |
Rash Erythematous |
2.8% |
Vomiting |
2.8% |
Hypotension |
2.6% |
Renal Tubular Disorder |
2.3% |
|
Secondary |
Product Used For Unknown Indication |
24.8% |
Drug Use For Unknown Indication |
15.4% |
Sepsis |
6.1% |
Infection |
6.1% |
Staphylococcal Infection |
4.9% |
Pneumonia |
4.9% |
Hypertension |
4.7% |
Prophylaxis |
3.8% |
Pyrexia |
3.7% |
Device Related Infection |
3.0% |
Endocarditis |
2.9% |
Acute Myeloid Leukaemia |
2.7% |
Osteomyelitis |
2.6% |
Pain |
2.5% |
Bacteraemia |
2.4% |
Cataract Operation |
2.2% |
Acute Lymphocytic Leukaemia |
1.9% |
Antibiotic Therapy |
1.9% |
Cellulitis |
1.8% |
Meningitis |
1.7% |
|
Renal Failure Acute |
13.7% |
Toxic Epidermal Necrolysis |
11.7% |
Drug Rash With Eosinophilia And Systemic Symptoms |
9.4% |
Thrombocytopenia |
7.2% |
Pyrexia |
6.2% |
Toxic Skin Eruption |
5.6% |
Renal Failure |
4.9% |
Tubulointerstitial Nephritis |
4.6% |
Stevens-johnson Syndrome |
3.8% |
Septic Shock |
3.8% |
Staphylococcal Infection |
3.8% |
Vomiting |
3.5% |
White Blood Cell Count Decreased |
3.5% |
Renal Impairment |
3.1% |
Rash |
3.0% |
Sepsis |
2.6% |
Toxic Anterior Segment Syndrome |
2.6% |
Myocardial Infarction |
2.5% |
Blood Creatinine Increased |
2.3% |
Drug Reaction With Eosinophilia And Systemic Symptoms |
2.3% |
|
Concomitant |
Product Used For Unknown Indication |
45.0% |
Drug Use For Unknown Indication |
18.7% |
Prophylaxis |
6.0% |
Pain |
3.0% |
Hypertension |
2.8% |
Acute Myeloid Leukaemia |
2.8% |
Coronary Artery Bypass |
2.3% |
Sepsis |
2.1% |
Pyrexia |
2.1% |
Infection |
2.0% |
Pneumonia |
1.9% |
Acute Lymphocytic Leukaemia |
1.9% |
Infection Prophylaxis |
1.5% |
Multiple Myeloma |
1.4% |
Staphylococcal Infection |
1.4% |
Nausea |
1.2% |
Febrile Neutropenia |
1.1% |
Constipation |
1.0% |
Adverse Event |
1.0% |
Sedation |
0.9% |
|
Vomiting |
9.1% |
Sepsis |
8.6% |
Thrombocytopenia |
7.8% |
Renal Failure |
6.1% |
White Blood Cell Count Decreased |
5.8% |
Pyrexia |
5.5% |
Renal Failure Acute |
5.5% |
Injury |
5.3% |
Pain |
5.3% |
Weight Decreased |
4.6% |
Pneumonia |
4.3% |
Respiratory Failure |
4.2% |
Unevaluable Event |
4.2% |
Death |
4.0% |
Anxiety |
3.5% |
Fear |
3.4% |
Septic Shock |
3.3% |
Multi-organ Failure |
3.2% |
White Blood Cell Count Increased |
3.1% |
Urinary Tract Infection |
3.1% |
|
Interacting |
Bronchopulmonary Aspergillosis |
31.3% |
Prophylaxis |
10.4% |
Aspergillosis |
10.0% |
Stem Cell Transplant |
8.0% |
Endocarditis |
7.0% |
Grand Mal Convulsion |
4.0% |
Sepsis |
4.0% |
Osteitis |
3.0% |
Postoperative Care |
3.0% |
Product Used For Unknown Indication |
3.0% |
Antiplatelet Therapy |
2.0% |
Candidiasis |
2.0% |
Diabetes Mellitus |
2.0% |
Drug Use For Unknown Indication |
2.0% |
Graft Versus Host Disease |
2.0% |
Premedication |
2.0% |
Septic Embolus |
1.5% |
Arthritis Infective |
1.0% |
Bacterial Infection |
1.0% |
Cardiac Disorder |
1.0% |
|
Drug Interaction |
21.6% |
Immunosuppressant Drug Level Decreased |
19.6% |
Sepsis |
13.7% |
Hypersensitivity |
11.8% |
Renal Failure Acute |
9.8% |
Overdose |
5.9% |
Mucocutaneous Candidiasis |
3.9% |
Hypokalaemia |
2.0% |
Infection |
2.0% |
Papule |
2.0% |
Proteus Infection |
2.0% |
Rash Erythematous |
2.0% |
Status Epilepticus |
2.0% |
Urticaria |
2.0% |
|